TruSight Tumor 170は、一般的な固形腫瘍に関連する170の遺伝子をカバーするように設計された次世代シーケンスアッセイで、DNAとRNAを同時に解析するエンリッチメントベースのターゲットパネルで、幅広い遺伝子とバリアントタイプをカバーします。包括的な性質により、ラボはがんの遺伝学を深く理解することができます。
装置 | 推奨サンプル数 | リード長 |
---|---|---|
NextSeq 550 System | ランあたりのサンプル数(高出力):16(8 DNA + 8 RNA)、DNAのみの場合は10、RNAのみの場合は16 | 2 × 101 bp(最大推奨) |
HiSeq 2500 System | ランごとのサンプル(高速ラン):12(6 DNA + 6 RNA)、6 DNAのみ、12 RNAのみ | 2 × 101 bp(最大推奨) |
TruSight Tumor 170 Panel enables translational researchers to seek answers to multiple questions in one assay.
Read InterviewLearn how Almac uses TruSight Tumor 170 in clinical cancer research for pharmaceutical and biotech clients.
Read ArticleStandard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.
Assessing DNA and RNA Quality from FFPE Samples for TruSight Tumor 170
White Paper | PDF < 1 MB
Detection of low-frequency variants in cfDNA using TruSight Tumor 170 with the TruSight UMI Toolkit
Application Note | PDF 2 MB
Application Note | PDF 2 MB
product_file | EXCEL < 1 MB
Data Sheet | PDF | 6 versions